SPADIN
- Product Name
- SPADIN
- CAS No.
- 1270083-24-3
- Chemical Name
- SPADIN
- Synonyms
- SPADIN;PubChem ID: 91826106;L-Arginine, L-tyrosyl-L-alanyl-L-prolyl-L-leucyl-L-prolyl-L-arginyl-L-tryptophyl-L-serylglycyl-L-prolyl-L-isoleucylglycyl-L-valyl-L-seryl-L-tryptophylglycyl-L-leucyl-
- CBNumber
- CB24734266
- Molecular Formula
- C96H142N26O22
- Formula Weight
- 2012.32
- MOL File
- 1270083-24-3.mol
SPADIN Property
- Density
- 1.46±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- Soluble to 2 mg/ml in H2O
- form
- solid
- pka
- 3.34±0.10(Predicted)
- color
- White
- Water Solubility
- Soluble in water (1 mg/ml)
N-Bromosuccinimide Price
- Product number
- 5594
- Product name
- Spadin
- Packaging
- 1
- Price
- $173
- Updated
- 2021/12/16
- Product number
- B6071
- Product name
- Spadin
- Packaging
- 1mg
- Price
- $251
- Updated
- 2021/12/16
SPADIN Chemical Properties,Usage,Production
Uses
Spadin is an anti-depressant molecule that blocks TREK-1 potassium channels.
Biological Activity
spadin is a potent trek-1 channel inhibitor with ic50 of 71nm. it is a secreted peptide derived from the propeptide generated by the maturation of ntsr3/sortilin. [1]trek-1, aka kcnk2, is a two-pore domain ion channel that involved in the passive transmembrane k+ transport. it is related to the ischemia, anesthesia and electrogenesis in the neurons. it also plays an important role in the pathophysiological process of depression and in the response to antidepressant. [1]in trek-1 transfected cos-7 cells, 100nm of spadin inhibited 63% of the trek-1 current stimulated by arachidnice acid. spadin also blocked the trek-1 channels activity in ca3 hippocampal neurons on brain slices of wild-type mice. [1]in behavioral tests that predicting an antidepressant response, spadin-treated mice displayed a resistance to depression. mice treated with spadin for 4 days also exhibited a significant antidepressant effect as well as elevated hippocampal phosphorylation of creb protein and neurogenesis. [2]
storage
-20°C
References
1. borsotto m, veyssiere j, moha ou maati h et al. targeting two-pore domain k(+) channels trek-1 and task-3 for the treatment of depression: a new therapeutic concept. br j pharmacol. 2015 feb;172(3):771-84.2. mazella j, pétrault o, lucas g, et al. spadin, a sortilin-derived peptide, targeting rodent trek-1 channels: a new concept in the antidepressant drug design. plos biol. 2010 apr 13;8(4):e1000355.